Xerox Expands Software Portfolio with Acquisition of CareAR
28.1.2021 17:00:00 EET | Business Wire | Press release
Xerox Holdings Corporation (NYSE: XRX) has expanded its growing software portfolio with the acquisition of CareAR, an augmented reality support platform company that provides real-time access to expertise for customers, employees, and field workers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210128005635/en/
CareAR is the latest addition to a suite of solutions in Xerox’s portfolio, aimed at providing digital transformation tools for its customers. (Photo: Business Wire)
With CareAR™ software, remote agents and experts can virtually see the situation and visually guide a solution using a suite of augmented reality tools via desktop, mobile, and smart glass devices, as if they were in-person.
Today, one-third of field service on-site calls require remote expert assistance to resolve issues but cannot effectively communicate the context of the situation. This causes delays, creating negative customer perception while risking loyalty and retention. Equipment downtime can be costly, running organizations between $300,000 and $5 million per hour, depending on the company’s size.1
“Our software solutions address some of the biggest needs for customers – content management, digital transformation and personalized communications. And now we’ve added enterprise augmented reality,” said Steve Bandrowczak, president and chief operations officer, Xerox. “By combining DocuShare®, XMPie and CareAR, we have a Software business that can together and apart support a wide range of clients’ needs.”
This expanded Software business will be led by Sam Waicberg, vice president and general manager of Digital Services for Xerox and former CareAR Co-founder and CEO prior to acquisition.
CareAR’s platform seamlessly integrates with workflow leader ServiceNow, ensuring an end-to-end approach to work orders, cases and incidents for full visibility and better troubleshooting.
“CareAR’s augmented reality software, which is integrated and certified with ServiceNow, helps customers remotely view and solve service issues,” says Michael Ramsey, vice president of Customer Workflow Product Management at ServiceNow. “Xerox’s acquisition of this technology can help drive further opportunities to modernize field service, customer support and IT services leveraging the power of the Now Platform and CareAR.”
Today, ServiceNow is collaborating with Deloitte to integrate the CareAR platform for ServiceNow® into the operations service systems and support workflows for joint clients.
“Xerox’s CareAR augmented reality platform provides us an ability to extend our market leading, industry-focused ServiceNow offerings.” said Asish Ramchandran, principal, Deloitte Consulting LLP. “CareAR represents the next mile in the digital transformation journey of organizations and together we have the ability to deliver next generation solutions that drive greater outcomes and value for our collective clients.”
CareAR is the latest addition to a series of solutions Xerox has launched to provide digital transformation tools to customers. These include automation and centralization solutions like DocuShare, a content management platform providing robust tools to automate processes and support cloud-enabled digital transformation; and XMPie, a flexible technology that allows customization and personalization of assets across customer touchpoints, both online and offline, for full marketing campaign integration.
In acknowledgement of the acquisition, CareAR is offering a free trial, found here: CareAR Trial. Offer valid starting January 28, 2021.
About Xerox
Xerox Holdings Corporation makes every day work better. We are a workplace technology company building and integrating software and hardware for enterprises large and small. As customers seek to manage information across digital and physical platforms, Xerox delivers a seamless, secure and sustainable experience. Whether inventing the copier, the Ethernet, the laser printer or more, Xerox has long defined the modern work experience. Learn how that innovation continues at xerox.com.
1FieldPoint: The Numbers Behind First-Time Fix Rates You Should Know About
Note: To receive RSS news feeds, visit https://www.news.xerox.com. For open commentary, industry perspectives and views, visit
http://www.linkedin.com/company/xerox, http://twitter.com/xerox,
http://www.facebook.com/XeroxCorp, https://www.instagram.com/xerox/,
http://www.youtube.com/XeroxCorp.
Xerox® and DocuShare® are trademarks of Xerox in the United States and/or other countries.
CareAR™ is a trademark of CareAR, Inc. in the United States and/or other countries.
ServiceNow®, the ServiceNow logo, Now, and other ServiceNow marks are trademarks and/or registered trademarks of ServiceNow, Inc., in the United States and/or other countries.
Please see www.deloitte.com/us/about for a detailed description of their legal structure.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210128005635/en/
Contact information
Media:
Brianca Climons, Xerox, +1-214-846-7276, brianca.climons@xerox.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom